LEAP2 reduces preprandial and postprandial glucose responses and ad libitum food intake in obese men
In this medfyle
LEAP2, a ghrelin receptor antagonist, reduces preprandial, peak, and postprandial plasma glucose concentration as well as food intake in obese men.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.
